Introduction
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Your key questions answered
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Mitsubishi Tanabe's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Your key questions answered
- Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sector
- See how the launch of pipeline products will generate modest growth and offset expiring product declines for the company
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Operating costs and profit analysis
Mitsubishi Tanabe: PharmaVitae forecasts at a glance
Strategic insight
2007: Tanabe and Mitsubishi merge amid a wave of Japanese consolidation
2009–15: greater scale but slow growth
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY UPDATE
Latest prescription pharma product news
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q2 2010
Q1 2010
Q3 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
M&A history
Merger of Mitsubishi Pharma and Tanabe Seiyaku
M&A history: Mitsubishi Pharma
M&A history: Tanabe Seiyaku
M&A strategy
Current corporate structure
Pharmaceuticals segment
Other business segment
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
APPENDIX
References
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Operating costs and profit analysis
Mitsubishi Tanabe: PharmaVitae forecasts at a glance
Strategic insight
2007: Tanabe and Mitsubishi merge amid a wave of Japanese consolidation
2009–15: greater scale but slow growth
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY UPDATE
Latest prescription pharma product news
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q2 2010
Q1 2010
Q3 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
M&A history
Merger of Mitsubishi Pharma and Tanabe Seiyaku
M&A history: Mitsubishi Pharma
M&A history: Tanabe Seiyaku
M&A strategy
Current corporate structure
Pharmaceuticals segment
Other business segment
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
APPENDIX
References
